

## Launching New Corporate Venture Capital for the Healthcare and Bio Sector

### - Promotes investments in advanced biopharmaceuticals and next-generation antibody drugs -

LOTTE HOLDINGS CO., LTD.. (President and CEO: Genichi Tamatsuka) has established a healthcare and biopharmaceutical corporate venture capital (CVC) unit within its Group Corporate Strategy Office to invest in the biopharmaceutical and next-generation antibody drug sectors.

LOTTE Group prioritizes the healthcare and biopharmaceutical sector as part of its new growth strategy. In 2022, LOTTE HOLDINGS CO., LTD., the LOTTE Group holding company in Japan, and LOTTE Corporation, the LOTTE Group holding company in South Korea (headquarters: Seoul, South Korea; Chairman Akio Shigemitsu) jointly established LOTTE BIOLOGICS (headquarters: Seoul, South Korea; CEO: Richard Lee), a contract development and manufacturing organization (CDMO), to enter the healthcare and biopharmaceutical business domain.

To strengthen the Company's commitment to the healthcare and biopharmaceutical sectors, LOTTE HOLDINGS CO., LTD.. has established a corporate venture capital (CVC) fund dedicated to these areas. This initiative aims to rapidly incorporate cutting-edge information, facilitate access to new technologies, and promote investment in promising startups focusing on advanced biopharmaceuticals, including antibody drugs and antibody-drug conjugates (ADCs), as well as next-generation modalities (e.g., nucleic acid therapeutics, regenerative medicine, and gene therapy). The CVC will also support startups developing enabling technologies that underpin advanced biopharmaceuticals, such as linkers and payloads including anticancer agents. Our investment targets will span all stages, with a primary focus on early- and growth-stage companies in Japan and globally.

This corporate venture capital (CVC) initiative is led by Dr. Joon Paek (PhD, MBA), an advisor to LOTTE HOLDINGS CO., LTD.. In collaboration with LOTTE BIOLOGICS and external experts, we aim to create value for our portfolio companies by providing investment capital, as well as support in technology, business development, and manufacturing solutions. In addition to Dr. Paek, we plan to collaborate with external

biopharmaceutical experts and venture capital firms.

#### Joon Paek's Career History



2000: Completed Master's Program, Kyoto University

2005: Completed Doctoral Program, Brown University

2005: Director of R&D, Tissue Genesis, USA

2018: Vice President of Corporate Development, Metcela Inc.

2020: Advisors, Principal, Axil Capital Advisors Co., Ltd.

2021: Earned MBA, Graduate School of Business, Waseda University

2022: Advisor, LOTTE HOLDINGS CO., LTD..

2022: Outside Director, LOTTE BIOLOGICS

Through this corporate venture capital (CVC) initiative, LOTTE HOLDINGS CO., LTD.. will continue to support promising entrepreneurs and startups worldwide, aiming to realize a healthier society.

#### ■About the launch of the new CVC



Genichi Tamatsuka, the CEO of LOTTE HOLDINGS CO., LTD..

LOTTE HOLDINGS CO., LTD.. will boldly take on challenges to combine business assets from Japan and South Korea and achieve global growth. This CVC is a crucial first step toward establishing a platform that will drive innovation and future growth. We will promote various initiatives to become a leading player in the healthcare and wellness sectors.

### **About LOTTE BIOLOGICS**

Company Name	LOTTE BIOLOGICS
Headquarters	Seoul, South Korea
CEO	Richard Lee
URL	<a href="https://www.lottebiologics.com/en/">https://www.lottebiologics.com/en/</a>

LOTTE BIOLOGICS is a global CDMO established in Seoul, South Korea, in 2022 through a joint investment by the Korean and Japanese LOTTE Groups, with the mission of delivering high-quality biopharmaceuticals that enable a healthier world. In 2023, the company entered the biopharmaceutical CDMO business through the acquisition of Bristol Myers Squibb's biopharmaceutical manufacturing facility in Syracuse, New York, USA. In addition, LOTTE BIOLOGICS is currently constructing the Songdo Bio Campus in Incheon, which will consist of three state-of-the-art manufacturing plants along with supporting facilities.

### **About LOTTE HOLDINGS CO., LTD.**

Company Name	LOTTE HOLDINGS CO., LTD.
Headquarters	3-20-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan
Representative Director	Genichi Tamatsuka
Website	<a href="https://lotte-hd.com/">https://lotte-hd.com/</a>
CVC Website	<a href="https://lotte-hd.com/en/business/lifescience/bio-cvc/">https://lotte-hd.com/en/business/lifescience/bio-cvc/</a>

Starting with its core confectionery and ice cream businesses, LOTTE HOLDINGS has expanded into a wide range of business fields, including professional baseball team management, real estate, finance, corporate venture capital, hotels, and healthcare. Looking ahead, LOTTE HOLDINGS aims to drive further innovation in its core food business while pursuing new growth opportunities by leveraging business synergies between Japan and South Korea.

The LOTTE Group began its operations in 1948 with the manufacturing and selling of chewing gum in Tokyo, Japan. Today, with headquarters in both Japan and South Korea, the LOTTE Group operates across more than 30 countries and regions worldwide, spanning businesses including food, retail, finance, biopharmaceuticals, healthcare, data centers, hotels and resorts, entertainment, and construction. Guided

by its vision as a "Lifetime Value Creator," the LOTTE Group is committed to delivering sustainable value throughout every moment of people's lives.